{
    "response": "**Overall Treatment Decision:** Yes\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Intravenous Methylprednisolone\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** First-line treatment for acute demyelinating relapse Reduces inflammation and hastens functional recovery\n\n*   **Treatment:** Proton Pump Inhibitor (e.g., Omeprazole)\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Gastric protection against ulceration while on high-dose steroids\n\n*   **Treatment:** DVT Prophylaxis (LMWH)\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Patient has reduced mobility due to hemiparesis Obesity is an additional risk factor for thrombosis\n\n*   **Treatment:** Plasma Exchange (PLEX)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Reserve for use if there is insufficient response to corticosteroids May be considered early if NMOSD is confirmed and deficits are severe\n\n*   **Treatment:** Long-term Disease Modifying Therapy (e.g., Rituximab, Ocrelizumab)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Requires definitive diagnosis (MS vs NMOSD) via antibody status and CSF results Infection screening must be completed prior to initiation\n\n\ntreatments = [{\"treatment\": \"Intravenous Methylprednisolone\", \"timing\": \"Start Now\", \"reasons\": [\"First-line treatment for acute demyelinating relapse\", \"Reduces inflammation and hastens functional recovery\"]}, {\"treatment\": \"Proton Pump Inhibitor (e.g., Omeprazole)\", \"timing\": \"Start Now\", \"reasons\": [\"Gastric protection against ulceration while on high-dose steroids\"]}, {\"treatment\": \"DVT Prophylaxis (LMWH)\", \"timing\": \"Start Now\", \"reasons\": [\"Patient has reduced mobility due to hemiparesis\", \"Obesity is an additional risk factor for thrombosis\"]}, {\"treatment\": \"Plasma Exchange (PLEX)\", \"timing\": \"Delay\", \"reasons\": [\"Reserve for use if there is insufficient response to corticosteroids\", \"May be considered early if NMOSD is confirmed and deficits are severe\"]}, {\"treatment\": \"Long-term Disease Modifying Therapy (e.g., Rituximab, Ocrelizumab)\", \"timing\": \"Delay\", \"reasons\": [\"Requires definitive diagnosis (MS vs NMOSD) via antibody status and CSF results\", \"Infection screening must be completed prior to initiation\"]}]"
}